0001193125-24-027629.txt : 20240208 0001193125-24-027629.hdr.sgml : 20240208 20240208082701 ACCESSION NUMBER: 0001193125-24-027629 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240207 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acrivon Therapeutics, Inc. CENTRAL INDEX KEY: 0001781174 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825125532 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41551 FILM NUMBER: 24606960 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-207-8979 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 d750834d8k.htm 8-K 8-K
false 0001781174 0001781174 2024-02-07 2024-02-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2024

 

 

Acrivon Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41551   82-5125532

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

480 Arsenal Way, Suite 100

Watertown, Massachusetts

   02472
(Address of Principal Executive Offices)   (Zip Code)

(617) 207-8979

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   ACRV   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 7, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Ivana Magovcevic-Liebisch, Ph.D., J.D., as a director of the Company, effective February 8, 2024. A copy of the press release announcing the appointment of Dr. Magovcevic-Liebisch is attached as Exhibit 99.1 to this report.

There are no arrangements or understandings between Dr. Magovcevic-Liebisch and any other person pursuant to which Dr. Magovcevic-Liebisch was selected as a director. There are no transactions involving Dr. Magovcevic-Liebischthat would be required to be reported under Item 404(a) of Regulation S-K.

In connection with her appointment as a director of the Company, Dr. Magovcevic-Liebisch will enter into the Company’s standard indemnification agreement applicable to non-employee directors and will receive a stock option grant of 32,500 shares vesting over 3 years in monthly installments as well as cash compensation in accordance with the Company’s non-employee director compensation arrangements, as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 1, 2023.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit

Number

    Exhibit Description
99.1    Press Release of the Company, dated February 8, 2024
104    Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Acrivon Therapeutics, Inc.
Dated: February 8, 2024     By:  

/s/ Peter Blume-Jensen

    Name:   Peter Blume-Jensen, M.D., Ph.D.
    Title:   Chief Executive Officer and President
 EX-99.1 2 d750834dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

WATERTOWN, Massachusetts, February 8, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors.

“We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “She brings more than 25 years of experience spanning global business and R&D operations, including leading partnering activities, commercialization, research and development, as well as counseling on regulatory, legal and IP strategies. Her diverse and substantial expertise will benefit us as we advance our pipeline of novel compounds.”

Dr. Magovčević-Liebisch is the president and chief executive officer at Vigil Neuroscience, Inc., where she led the in-licensing deal that secured the company’s anchor assets from Amgen. Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs. Prior to Vigil, Dr. Magovčević-Liebisch was the executive vice president and chief business officer at Ipsen where she was responsible for growing the pipeline through strategic transactions. Before joining Ipsen, Dr. Magovčević-Liebisch served as senior vice president and head of global business development for the specialty drug business at Teva Pharmaceutical Industries Ltd. where she executed multiple transactions across different therapeutic areas and modalities. Prior to Teva, Dr. Magovčević-Liebisch held multiple pivotal roles at Dyax including executive vice president, chief operating officer, chief business officer, and general counsel. During her time, she established the commercial infrastructure for the company’s first approved drug with high-touch patient services, developed and executed IP strategy for a successful licensing program as well as equity financings, revenue monetization, corporate partnerships, and licensing agreements. Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation. She holds a Ph.D. in genetics from Harvard University and a J.D. in high technology law from Suffolk University Law School. She graduated from Wheaton College with a B.A. (summa cum laude) in biology and chemistry.

Dr. Magovčević-Liebisch added, “I am inspired by the pursuit of innovation, and I believe that Acrivon’s AP3 platform is poised to make a major impact in the field of precision medicine. I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”

About Acrivon Therapeutics

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally-discovered preclinical stage pipeline programs, including its development candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and an undisclosed cell cycle program.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:

Adam D. Levy, Ph.D., M.B.A.

alevy@acrivon.com

Alexandra Santos

asantos@wheelhouselsa.com

EX-101.SCH 3 acrv-20240207.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 acrv-20240207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 acrv-20240207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g750834g0208065252412.jpg GRAPHIC begin 644 g750834g0208065252412.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 07, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001781174
Document Type 8-K
Document Period End Date Feb. 07, 2024
Entity Registrant Name Acrivon Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41551
Entity Tax Identification Number 82-5125532
Entity Address, Address Line One 480 Arsenal Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 207-8979
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol ACRV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acrv-20240207.xsd acrv-20240207_lab.xml acrv-20240207_pre.xml d750834d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d750834d8k.htm": { "nsprefix": "acrv", "nsuri": "http://acrivon.com/20240207", "dts": { "schema": { "local": [ "acrv-20240207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "acrv-20240207_lab.xml" ] }, "presentationLink": { "local": [ "acrv-20240207_pre.xml" ] }, "inline": { "local": [ "d750834d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d750834d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d750834d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://acrivon.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-027629-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-027629-xbrl.zip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end XML 17 d750834d8k_htm.xml IDEA: XBRL DOCUMENT 0001781174 2024-02-07 2024-02-07 false 0001781174 8-K 2024-02-07 Acrivon Therapeutics, Inc. DE 001-41551 82-5125532 480 Arsenal Way Suite 100 Watertown MA 02472 (617) 207-8979 false false false false Common Stock, $0.001 par value ACRV NASDAQ true false